Aprea Therapeutics, Inc.
APRE
$0.79
-$0.04-5.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.31M | -11.95M | -12.60M | -13.04M | -13.85M |
| Total Depreciation and Amortization | 21.90K | 21.60K | 21.60K | 21.60K | 21.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 469.80K | 535.50K | 612.50K | 542.50K | 607.70K |
| Change in Net Operating Assets | -352.60K | -622.40K | -929.20K | -969.70K | 479.50K |
| Cash from Operations | -12.17M | -12.02M | -12.89M | -13.44M | -12.74M |
| Capital Expenditure | -15.40K | -- | -- | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -15.40K | -- | -- | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 40.19M | 40.09M | 5.05M | 975.20K | 599.80K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.30M | -878.70K | -407.40K | -42.10K | -25.90K |
| Cash from Financing | 36.89M | 39.21M | 4.64M | 933.00K | 573.90K |
| Foreign Exchange rate Adjustments | -300.00 | 3.00K | 4.70K | -21.20K | 4.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.70M | 27.19M | -8.25M | -12.53M | -12.16M |